Biotech short sellers are “right” about 30–50% of the timeover the long term—but even that is generous. Many funds face significant losses from sharp, sudden price spikes on trial data or approvals. Shorts in biotech are often wrong or mistimed.
A 2019 study by S3 Partners found thatbiotech was one of the least profitable sectors for short sellers—mainly due to unpredictable binary events like FDA decisions or trial results.
CU6 Price at posting:
$2.25 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)